Incyte Corporation
INCYIncyte Corporation is an American multinational pharmaceutical company with headquarters in Wilmington, Delaware. The company currently operates manufacturing and R&D locations in North America, Europe, and Asia.
Drugs in Pipeline
53
Phase 3 Programs
19
Upcoming Catalysts
15
Next Catalyst
This month
Market Overview
Stock performance and key metrics
15 upcoming, 3 past
Ruxolitinib Cream Phase 3 Est. Readout
Estimated primary completion for Ruxolitinib Cream trial (NCT06958211) in Hidradenitis Suppurativa. Topline data typically follows completion by weeks to months.
Source14 more catalysts beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
How INCY's past catalysts played out
Povorcitinib
NonSegmental Vitiligo
Itacitinib
MPN (Myeloproliferative Neoplasms)
ruxolitinib tablets
Polycythemia Vera
pembrolizumab + epacadostat
Melanoma
Hydroxyurea (HU)
Polycythemia Vera
Corticosteroids
Chronic Graft-versus-host-disease
Ruxolitinib Cream
Nonsegmental Vitiligo With Genital Involvement
Ruxolitinib
MPN (Myeloproliferative Neoplasms)
Extracorporeal photopheresis (ECP)
Graft-versus-host Disease (GVHD)
Retifanlimab
Metastatic Merkel Cell Carcinoma
Tafasitamab
Diffuse Large B Cell Lymphoma
Bendamustine (BEN)
Diffuse Large B-cell Lymphoma
INCB123667
Ovarian Cancer
Investigator's choice of chemotherapy
Ovarian Cancer
INCA33890
CRC (Colorectal Cancer)
INCB161734
Solid Tumors
Tacrolimus (Tac)
Graft-versus-host Disease (GVHD)
Epacadostat
Lung Cancer
INCA034176
Chronic Graft-versus-host-disease
Best available Treatment (BAT)
Chronic Graft-versus-host-disease
INCB018424
Rheumatoid Arthritis
INCB028050
Rheumatoid Arthritis
Prednisone or methylprednisolone
Graft-versus-host Disease (GVHD)
Ruxolitinib Phosphate
Psoriasis
Immune effector cell therapy
Cytokine Release Syndrome
Platinum-based chemotherapy
Lung Cancer
parsaclisib + itacitinib
B-Cell Malignancies
MEDI4736
Solid Tumors
Ruxolitinib 1.5% cream
Vitiligo
Regorafenib
Pancreatic Cancer
MK-3475
Microsatellite-instability (MSI) High Colorectal Cancer (CRC)
INCA000585
Immune Thrombocytopenia
INCAGN01876
Advanced Malignancies
INCAGN01949
Advanced Malignancies
R-CHOP
Non Hodgkins Lymphoma
INCB001158
Biliary Tract Cancer (BTC)
INCB177054
Solid Tumors
ICS-LABA
Moderate to Severe Asthma
Pemigatinib
Non-Small Cell Lung Cancer (NSCLC)
Ruxolitinib 25 mg
Multiple Myeloma
Asparaginase Erwinia Chrysanthemi
Leukemia
INCB013739
Type 2 Diabetes
INCB000928
Anemia
Ruxolitinib phosphate cream
Psoriasis
INCB054707
Hidradenitis Suppurativa
Parsaclisib
B-Cell Malignancies
Ponatinib
Philadelphia Positive
Ruxolitinib 0.15% Cream QD
Atopic Dermatitis
INCB009471
HIV Infections
INCB099280
Advanced Solid Tumor
INCAGN02385
Endometrial Cancer
Axatilimab
Chronic Graft-versus-host-disease
INCAGN02390
Melanoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Povorcitinib | Phase 3 | NonSegmental Vitiligo | - | - |
Itacitinib | Phase 3 | MPN (Myeloproliferative Neoplasms) | - | - |
ruxolitinib tablets | Phase 3 | Polycythemia Vera | - | - |
pembrolizumab + epacadostat | Phase 3 | Melanoma | - | - |
Hydroxyurea (HU) | Phase 3 | Polycythemia Vera | - | - |
Corticosteroids | Phase 3 | Chronic Graft-versus-host-disease | - | - |
Ruxolitinib Cream | Phase 3 | Nonsegmental Vitiligo With Genital Involvement | - | - |
Ruxolitinib | Phase 3 | MPN (Myeloproliferative Neoplasms) | - | Patent 2041 |
Extracorporeal photopheresis (ECP) | Phase 3 | Graft-versus-host Disease (GVHD) | - | - |
Retifanlimab | Phase 3 | Metastatic Merkel Cell Carcinoma | - | - |
Tafasitamab | Phase 3 | Diffuse Large B Cell Lymphoma | - | - |
Bendamustine (BEN) | Phase 3 | Diffuse Large B-cell Lymphoma | - | - |
INCB123667 | Phase 3 | Ovarian Cancer | - | - |
Investigator's choice of chemotherapy | Phase 3 | Ovarian Cancer | - | - |
INCA33890 | Phase 3 | CRC (Colorectal Cancer) | - | - |
INCB161734 | Phase 3 | Solid Tumors | - | - |
Tacrolimus (Tac) | Phase 3 | Graft-versus-host Disease (GVHD) | - | - |
Epacadostat | Phase 3 | Lung Cancer | - | - |
INCA034176 | Phase 3 | Chronic Graft-versus-host-disease | - | - |
Best available Treatment (BAT) | Phase 2 | Chronic Graft-versus-host-disease | - | - |
INCB018424 | Phase 2 | Rheumatoid Arthritis | - | - |
INCB028050 | Phase 2 | Rheumatoid Arthritis | - | - |
Prednisone or methylprednisolone | Phase 2 | Graft-versus-host Disease (GVHD) | - | - |
Ruxolitinib Phosphate | Phase 2 | Psoriasis | - | - |
Immune effector cell therapy | Phase 2 | Cytokine Release Syndrome | - | - |
Platinum-based chemotherapy | Phase 2 | Lung Cancer | - | - |
parsaclisib + itacitinib | Phase 2 | B-Cell Malignancies | - | - |
MEDI4736 | Phase 2 | Solid Tumors | - | - |
Ruxolitinib 1.5% cream | Phase 2 | Vitiligo | - | - |
Regorafenib | Phase 2 | Pancreatic Cancer | - | - |
MK-3475 | Phase 2 | Microsatellite-instability (MSI) High Colorectal Cancer (CRC) | - | - |
INCA000585 | Phase 2 | Immune Thrombocytopenia | - | - |
INCAGN01876 | Phase 2 | Advanced Malignancies | - | - |
INCAGN01949 | Phase 2 | Advanced Malignancies | - | - |
R-CHOP | Phase 2 | Non Hodgkins Lymphoma | - | - |
INCB001158 | Phase 2 | Biliary Tract Cancer (BTC) | - | - |
INCB177054 | Phase 2 | Solid Tumors | - | - |
ICS-LABA | Phase 2 | Moderate to Severe Asthma | - | - |
Pemigatinib | Phase 2 | Non-Small Cell Lung Cancer (NSCLC) | - | Patent 2040 |
Ruxolitinib 25 mg | Phase 2 | Multiple Myeloma | - | - |
Asparaginase Erwinia Chrysanthemi | Phase 2 | Leukemia | - | - |
INCB013739 | Phase 2 | Type 2 Diabetes | - | - |
INCB000928 | Phase 2 | Anemia | - | - |
Ruxolitinib phosphate cream | Phase 2 | Psoriasis | - | Patent 2041 |
INCB054707 | Phase 2 | Hidradenitis Suppurativa | - | - |
Parsaclisib | Phase 2 | B-Cell Malignancies | - | - |
Ponatinib | Phase 2 | Philadelphia Positive | - | - |
Ruxolitinib 0.15% Cream QD | Phase 2 | Atopic Dermatitis | - | - |
INCB009471 | Phase 2 | HIV Infections | - | - |
INCB099280 | Phase 2 | Advanced Solid Tumor | - | - |
INCAGN02385 | Phase 2 | Endometrial Cancer | - | - |
Axatilimab | Phase 2 | Chronic Graft-versus-host-disease | - | - |
INCAGN02390 | Phase 2 | Melanoma | - | - |
Chronic Graft-versus-host-disease
3 drugs in this indication
Melanoma
2 drugs in this indication
Graft-versus-host Disease (GVHD)
2 drugs in this indication
Hidradenitis Suppurativa
2 drugs in this indication
Polycythemia Vera
2 drugs in this indication
MPN (Myeloproliferative Neoplasms)
2 drugs in this indication
Nonsegmental Vitiligo With Genital Involvement
1 drug in this indication
Atopic Dermatitis
1 drug in this indication
Leukemia
1 drug in this indication
HIV Infections
1 drug in this indication
immune-resistant RCC
1 drug in this indication
Philadelphia Positive
1 drug in this indication
Solid Tumors
1 drug in this indication
Non-Small Cell Lung Cancer (NSCLC)
1 drug in this indication
Prurigo Nodularis
1 drug in this indication
Psoriasis
1 drug in this indication
Metastatic Merkel Cell Carcinoma
1 drug in this indication
Non-segmental Vitiligo
1 drug in this indication
Multiple Myeloma
1 drug in this indication
B-Cell Malignancies
1 drug in this indication
Diffuse Large B Cell Lymphoma
1 drug in this indication
Anemia
1 drug in this indication
Ovarian Cancer
1 drug in this indication
Advanced Solid Tumor
1 drug in this indication
NonSegmental Vitiligo
1 drug in this indication
Biliary Tract Cancer (BTC)
1 drug in this indication
Moderate to Severe Asthma
1 drug in this indication
Endometrial Cancer
1 drug in this indication
essential thrombocythemia
1 drug in this indication
Type 2 Diabetes
1 drug in this indication
rare bone disorder
1 drug in this indication
Fibrodysplasia Ossificans Progressiva
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Incyte Corporation's drug pipeline?→
CatalystAlert tracks 53 drug candidates in Incyte Corporation's (INCY) pipeline across Phase 3, Phase 2. Its lead program is Povorcitinib (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Incyte Corporation's next FDA catalyst?→
Incyte Corporation's (INCY) next tracked catalyst is a Conference expected October 1, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track INCY biotech catalysts?→
Add INCY to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Incyte Corporation's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.